| Chapter title |
Development of Therapeutic dsP21-322 for Cancer Treatment
|
|---|---|
| Chapter number | 16 |
| Book title |
RNA Activation
|
| Published in |
Advances in experimental medicine and biology, June 2017
|
| DOI | 10.1007/978-981-10-4310-9_16 |
| Pubmed ID | |
| Book ISBNs |
978-9-81-104309-3, 978-9-81-104310-9
|
| Authors |
Moo Rim Kang, Gongcheng Li, Tiejun Pan, Jin-Chun Xing, Long-Cheng Li |
| Editors |
Long-Cheng Li |
| Abstract |
Small activating RNAs (saRNAs) are a class of artificially designed short duplex RNAs targeted at the promoter of a particular gene to upregulate its expression via a mechanism known as RNA activation (RNAa) and hold great promise for treating a wide variety of diseases including those undruggable by conventional therapies. The therapeutic benefits of saRNAs have been demonstrated in a number of preclinical studies carried out in different disease models including cancer. With many tumor suppressor genes (TSGs) downregulated due to either epigenetic mechanisms or haploinsufficiency resulting from deletion/mutation, cancer is an ideal disease space for saRNA therapeutics which can restore the expression of TSGs via epigenetic reprogramming. The p21(WAF1/CIP) gene is a TSG frequently downregulated in cancer and an saRNA for p21(WAF1/CIP) known as dsP21-322 has been identified to be a sequence-specific p21(WAF1/CIP) activator in a number of cancer types. In this chapter, we review preclinical development of medicinal dsP21-322 for cancer, especially prostate cancer and bladder cancer, and highlight its potential for further clinical development. |
Mendeley readers
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 9 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 2 | 22% |
| Student > Doctoral Student | 1 | 11% |
| Other | 1 | 11% |
| Student > Ph. D. Student | 1 | 11% |
| Professor > Associate Professor | 1 | 11% |
| Other | 0 | 0% |
| Unknown | 3 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 3 | 33% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 11% |
| Computer Science | 1 | 11% |
| Agricultural and Biological Sciences | 1 | 11% |
| Unknown | 3 | 33% |